'Icahn alleges that Thompson and deSouza championed a “reckless decision” to close Illumina’s $8bn acquisition of cancer test developer Grail in 2021 against the wishes of EU and US antitrust regulators. Illumina’s market capitalisation has plunged from $75bn in August 2021, when it bought Grail, to just over $32bn on Tuesday.'

https://www.ft.com/content/16021817-6202-4f38-8af9-3932bf555aa8